Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse.

@article{Stentoft2006MinimalRC,
  title={Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse.},
  author={Jesper Stentoft and Peter Hokland and Mette Ostergaard and Henrik Hasle and Charlotte G Nyvold},
  journal={Leukemia research},
  year={2006},
  volume={30 4},
  pages={
          389-95
        }
}
Minimal residual disease (MRD) was measured by RQ-PCR in 11 AML1/ETO and 13 CBFbeta/MYH11 patients at diagnosis, after induction chemotherapy, and at all subsequent visits. Median detection limits were 1:50,000 and 1:10,000, respectively. In 64/103 samples MRD was detectable and highly correlated in PB and BM. In 38/103 samples, where MRD was only detectable in BM, median BM MRD was 3.5log lower than at diagnosis. Event free survival was significantly inferior in case of <2log reduction post… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13).

  • Journal of pediatric hematology/oncology
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Response kinetics and factors predicting survival in core-binding factor leukemia

Prajwal Boddu, Christopher Gurguis, +10 authors Gautam Borthakur
  • Leukemia
  • 2018